Loading clinical trials...
Loading clinical trials...
A Study to Evaluate the Efficacy and Safety of RNK08954 in Subjects With KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Conditions
Interventions
RNK08954
Locations
2
China
Nanjing Tianyinshan Hospital
Nanjing, China
Shanghai GoBroad Cancer Hospital China Pharmaccutical University
Shanghai, China
Start Date
October 14, 2025
Primary Completion Date
November 30, 2026
Completion Date
November 30, 2026
Last Updated
December 24, 2025
NCT07542041
NCT07030283
NCT06040541
NCT06639724
NCT07373691
NCT07458347
Lead Sponsor
Ranok Therapeutics (Hangzhou) Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions